Aardvark therapeutics reports first quarter 2025 financial results and provides business highlights

Phase 3 hero trial of ard-101 for the treatment of hyperphagia associated with prader-willi syndrome (pws); data readout expected in early 2026 $151.3 million in cash, cash equivalents, and short-term investments supports projected operations into 2027 san diego, may 14, 2025 (globe newswire) -- aardvark therapeutics, inc. (aardvark) (nasdaq: aard), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the first quarter ended march 31, 2025, and provided business highlights. “we believe that there is a significant, untapped opportunity to target anti-hunger signaling to treat rare metabolic diseases and obesity.
AARD Ratings Summary
AARD Quant Ranking